Multiple myeloma developing during long-term clinical course of refractory immune thrombocytopenic purpura: a case report and review of literature.
Yao H, Zhang X, Liu J, Zhu L, Chen G, Wu S, Gao L.
Int J Clin Exp Pathol. 2015 Nov 1;8(11):15429-32. eCollection 2015.
PMID:26823908
Coexisting Thalassemia, Immune Thrombocytopenic Purpura, and Multiple Myeloma With Osteopenia: Complex Hematologic Case in an Adult Asian Male Patient.
Chambi-Torres JB, Angly S, Michel G.
Cureus. 2024 Dec 8;16(12):e75338. doi: 10.7759/cureus.75338. eCollection 2024 Dec.
PMID:39776720
Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy.
Qiu L, Zhu F, Wei G, Wu W, Yang L, Hu Y, Huang H.
Regen Ther. 2020 May 15;14:271-274. doi: 10.1016/j.reth.2020.03.005. eCollection 2020 Jun.
PMID:32455157
Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib.
Moore H, Romeril K.
Intern Med J. 2011 Apr;41(4):348-50. doi: 10.1111/j.1445-5994.2011.02458.x.
PMID:21507163
Immune thrombocytopenia purpura associated with multiple myeloma.
Faller E, Chapman L, Enright H, Browne P, McHugh J, Desmond R.
Ann Hematol. 2016 Aug;95(8):1371-2. doi: 10.1007/s00277-016-2694-y. Epub 2016 May 13.
PMID:27178045
Autoimmune Complications in Hematologic Neoplasms.
Barcellini W, Giannotta JA, Fattizzo B.
Cancers (Basel). 2021 Mar 26;13(7):1532. doi: 10.3390/cancers13071532.